Table 3.
Variable | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
T90 (<5.0 min) | Reference | — | Reference | — |
T90 (5.0–52.0 min) | 1.39 (1.08–1.79) | 0.011 | 1.32 (1.02–1.71) | 0.034 |
T90 (>52.0 min) | 1.80 (1.41–2.30) | <0.001 | 1.56 (1.21–2.02) | 0.001 |
Age ≥ 60 years | 1.40 (1.15–1.70) | 0.001 | 1.20 (0.98–1.47) | 0.086 |
BMI ≥ 28 kg/m2 | 0.76 (0.59–0.96) | 0.022 | — | — |
NYHA III/IV | 1.44 (1.08–1.92) | 0.013 | — | — |
CAD | 1.21 (0.99–1.48) | 0.068 | — | — |
Hypertension | 0.79 (0.65–0.96) | 0.017 | 0.77 (0.63–0.95) | 0.014 |
Atrial fibrillation | 1.37 (1.12–1.67) | 0.002 | — | — |
BUN, mg/dL | 1.06 (1.04–1.08) | <0.001 | 1.04 (1.01–1.06) | 0.002 |
eGFR < 60, mL/min/1.73 m2 | 1.48 (1.21–1.81) | <0.001 | — | — |
LAD, mm | 1.03 (1.02–1.04) | <0.001 | 1.03 (1.02–1.04) | <0.001 |
LVEDD, mm | 1.00 (0.99–1.01) | 0.849 | 0.99 (0.98–1.00) | 0.045 |
LnNT‐proBNP, pg/mL | 1.43 (1.31–1.56) | <0.001 | 1.24 (1.12–1.36) | <0.001 |
LVEF | 0.028 | — | ||
40–49% | 0.71 (0.52–0.97) | 0.031 | — | — |
≥50% | 1.15 (0.91–1.45) | 0.256 | — | — |
ACEIs/ARBs | 0.52 (0.43–0.64) | <0.001 | 0.66 (0.54–0.82) | <0.001 |
Beta‐blockers | 0.93 (0.66–1.33) | 0.709 | — | — |
MRAs | 0.87 (0.69–1.08) | 0.866 | — | — |
Digoxin | 1.00 (0.82–1.22) | 0.998 | — | — |
Loop diuretics | 0.89 (0.59–1.35) | 0.588 | 0.62 (0.41–0.95) | 0.028 |
ACEIs, angiotensin‐converting enzyme inhibitors; ARBs, angiotensin receptor blockers; BMI, body mass index; BUN, blood urea nitrogen; CAD, coronary artery disease; CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; LAD, left atrial diameter; LVEDD, left ventricular end‐diastolic diameter; LVEF, left ventricular ejection fraction; MRAs, mineralocorticoid receptor antagonists; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; NYHA, New York Heart Association; T90, time < 90% oxygen saturation.